Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Maintains $62 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Geulah Livshits has reiterated a Buy rating on Rocket Pharmaceuticals (NASDAQ:RCKT) and maintained a price target of $62.
August 06, 2024 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital analyst Geulah Livshits has reiterated a Buy rating on Rocket Pharmaceuticals and maintained a price target of $62.
The reiteration of a Buy rating and a maintained price target of $62 by Chardan Capital is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100